Hormonal Causes of Menstrual-Related Mood Disorders

NCT00100360 | Completed

• 2 other identifiers: 05005905-M-0059
• Study Type: observational
• Target: 22
• Locations: 1 country
• Sites: 1

Brief Summary

This study will explore possible hormonal causes of menstrual-related mood disorders (MRMD) by stopping the menstrual cycle with a drug called Lupron and then giving in sequence two menstrual cycle hormones, progesterone and estrogen. The study will first evaluate Lupron's effectiveness in treating MRMD and will then examine the effects of giving estrogen and progesterone on mood and behavior. In addition, positron emission tomography (PET) and magnetic resonance imaging (MRI) will be used to study serotonin receptors and transporters - molecules in the brain that are thought to play a major role in mood changes related to the menstrual cycle. Menstruating women between 18 and 50 years of age who are in good health, not pregnant, and not taking medications may be eligible for this study. Women with MRMD must have had at least moderately severe MRMD or behavioral disturbances for at least 6 months within 2 years of entering the study. Healthy controls must have no history of MRMD or behavioral disturbances. Candidates undergo physical and neurological examinations, chest x-ray, electrocardiogram, and blood and urine tests. Results of a recent Pap smear (no longer than 12 months before beginning the study) must be available. Participants undergo the following tests and procedures:

• Drug treatment: Lupron is injected into a muscle once a month for 5 months. After the second month, participants receive estrogen or progesterone, or both, daily. Estrogen is delivered through a skin patch (20 micrograms per day) and the progesterone is taken as a rectal or vaginal suppository twice a day for the remaining 12 weeks of the study. Every day, all participants wear a skin patch and insert two suppositories, but at some point during the 12 weeks, active medication is replaced with placebo to allow the drugs to wash out of the body.
• Physical examination and blood draw: A physical examination and blood tests are done at the start of the study and several times during the study to assess general health, evaluate liver and kidney function, and measure blood cell counts.
• Response to treatment drugs: Responses to Lupron, estrogen, and progesterone are evaluated periodically with interviews and symptoms self-rating scales. Control subjects also take paper and pencil psychological tests.
• PET imaging: A total of six PET scans are done at three time points during hormone treatment. PET uses small amounts of a radioactive chemical called a tracer that "labels" active areas of the brain. For the procedure, the subject lies on the scanner bed. A special mask is fitted to the head and attached to the bed to help keep the subject's head still during the scan so the images will be clear. A brief scan is done just before the radioactive tracer is injected to help in analyzing the PET data. After the tracer is injected through a catheter (plastic tube) placed in the arm, pictures are taken for about 2 hours, during which the subject lies still on the scanner bed.
• MRI scan: MRI uses a magnetic field and radio waves to produce images of body tissues and organs. For this procedure, the patient lies on a table that is moved into the scanner (a narrow cylinder) and wears earplugs to muffle loud knocking and thumping sounds that occur during the scanning process. The procedure lasts about 1 hour.

Conditions

Mood Disorders; Depression

Keywords

Gonadal Steroids; GnRH Agonist; Depression; Menstrual Cycle; Menstrually Related Mood Disorder; MRMD; Healthy Volunteer; HV

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: female
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Women who meet the criteria for MRMD will have participated in Protocol No. 81-M-0126, The Evaluation of Women with Menstrually Regulated Mood and Behavior Disorders:
• Women with MRMD:
• History within the last two years of at least six months with menstrually-related mood or behavioral disturbances of at least moderate severity-i.e., disturbances that are distinct in appearance and associated with a notable degree of subjective distress.
• Symptoms should have a sudden onset and offset.
• age 18-50.
• Not pregnant and in good medical health.
• Medication free.
• No prior DSM-IV Axis I disorder.
• No prior history of treatment with antidepressant medications
• All patients participating in this protocol will have already participated in protocol No. 81-M-0126 and will have a prospectively confirmed and predictable relationship between their mood disorder and the premenstrual phase of the menstrual cycle; i.e., a 30% change in severity of symptom self rating scales, relative to the range of the scale employed, during the seven days premenstrually compared with the seven days post-menstrually in two out of three months of study.
• Women without MRMD:
• No history of menstrual-related mood or behavioral disturbances;
• Age 18 and 50 years;
• Not pregnant;
• Good medical health;

You may not qualify if:

• Results of PAP smear performed not longer than 12 months prior to onset of treatment will be obtained. Subjects taking birth control pills or diuretics will be excluded from the study, as will patients taking psychotropic agents (e.g., lithium carbonate, tricyclic antidepressants). All subjects will be required to use non-hormonal forms of birth control (e.g., barrier methods) to avoid pregnancy during this study.
• The following conditions will constitute contraindications to treatment with hormonal therapy and will preclude a subject's participation in this protocol.
• History consistent with endometriosis.
• Diagnosis of ill-defined, obscure pelvic lesions, particularly undiagnosed ovarian enlargement.
• Hepatic disease as manifested by abnormal liver function test.
• History of mammary carcinoma.
• History of pulmonary embolism or phlebothrombosis.
• Undiagnosed vaginal bleeding.
• Porphyria.
• Diabetes mellitus.
• History of malignant melanoma.
• Cholecystitis or pancreatitis.
• Cardiovascular or renal disease.
• Pregnancy.
• Any woman meeting the Stages of Reproductive Aging Workshop Criteria (STRAW) for the perimenopause. Specifically, we will exclude any woman with an elevated plasma FSH level (\> 14 IU/L) and with menstrual cycle variability of \> 7 days different from their normal cycle length.

Sponsors & Collaborators

• National Institute of Mental Health (NIMH): lead

Study Sites (1)

National Institutes of Health Clinical Center, 9000 Rockville Pike

Bethesda, Maryland, 20892, United States

Location

Related Publications (3)

• McEwen BS, Alves SE. Estrogen actions in the central nervous system. Endocr Rev. 1999 Jun;20(3):279-307. doi: 10.1210/edrv.20.3.0365. No abstract available.

  PMID: 10368772 BACKGROUND

• Osterlund MK, Halldin C, Hurd YL. Effects of chronic 17beta-estradiol treatment on the serotonin 5-HT(1A) receptor mRNA and binding levels in the rat brain. Synapse. 2000 Jan;35(1):39-44. doi: 10.1002/(SICI)1098-2396(200001)35:13.0.CO;2-T.

  PMID: 10579806 BACKGROUND

• Lu NZ, Bethea CL. Ovarian steroid regulation of 5-HT1A receptor binding and G protein activation in female monkeys. Neuropsychopharmacology. 2002 Jul;27(1):12-24. doi: 10.1016/S0893-133X(01)00423-7.

  PMID: 12062903 BACKGROUND

MeSH Terms

Conditions

Mood Disorders; Depression

Condition Hierarchy (Ancestors)

Mental Disorders; Behavioral Symptoms; Behavior

Study Officials

• Peter J Schmidt, M.D.

  National Institute of Mental Health (NIMH)

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Sponsor Type: NIH
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 29, 2004
• First Posted: December 30, 2004
• Study Start: December 22, 2004
• Study Completion: December 15, 2016
• Last Updated: July 5, 2018

Record last verified: 2016-12-15

Locations

US (1)